Shanghai:603259

WuXi AppTec Achieved Strong Growth in First-Half of 2020 with China Sites Resuming Full Operations

WuXi AppTec Second-Quarter 2020 Results Revenue Up 29.4% YoY to RMB4,044 Million Net Profit Attributable to Owners of the Company Up 111.0% YoY to RMB1,414 Million Diluted EPS Up 110.3% YoY to RMB0.61 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 43.1% YoY toRMB942 Million...

2020-08-13 16:49 3573

WuXi AppTec Reports Solid First-Quarter 2020 Results

SHANGHAI, April 29, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and del...

2020-04-29 17:30 7833

WuXi AppTec Reports Strong 2019 Annual Results

Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 38.2% Year-Over-Year toRMB2,407 Million Adjusted Diluted Non-IFRS EPS Up by 19.7% to RMB1.46[1] SHANGHAI, March 24, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. ...

2020-03-24 18:56 5743

WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform

PHILADELPHIA, Jan. 13, 2020 /PRNewswire/ -- WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advance therapies industry, announced today the expansion of its service capabilities by offering a fully ...

2020-01-13 22:00 5467

WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility

SHANGHAI, Jan. 2, 2020 /PRNewswire/ -- STA Pharmaceutical Co., Ltd.,  (WuXi STA) – a subsidiary of WuXi AppTec – today announced the opening of its large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility inChangzhou, China. This signifi...

2020-01-03 08:10 955

WuXi AppTec Receives Investment Grade Corporate Ratings from Three Global Rating Agencies

SHANGHAI, Nov. 6, 2019 /PRNewswire/ -- WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P Global Ratings (BBB-), and Fitch Ratings (BBB-); all three agencies maintain a stable outlook on WuXi AppTec. Th...

2019-11-06 16:00 476

WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules

SHANGHAI and CAMBRIDGE, Massachusetts and SANKT AUGUSTIN, Germany, Oct. 10, 2019 /PRNewswire/ -- WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's library of novel drug-like scaffolds, GalaXi® offers a...

2019-10-11 08:02 6619

WuXi AppTec Reports First Half 2019 Interim Results

* Revenue Accelerated 33.7% Year-Over-Year to RMB 5,894 Million * Gross Profit Up 30.0% Year-Over-Year to RMB 2,284 million[1] * Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year toRMB 1,179 Million * Small Molecule CDMO/CMO Pipeline has Grown to 800...

2019-08-19 19:20 1829

WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections

SHANGHAI, July 23, 2019 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit (ASU) inShanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have successfully passed two...

2019-07-23 12:48 1939

WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies

SHANGHAI, June 29, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2019. WuXi was chosen for its ded...

2019-06-29 13:26 9158

WuXi AppTec Acquires Pharmapace to Enhance Biometrics Services for Clinical Development

SHANGHAI and SAN DIEGO, May 5, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced that it has acquired Pharmapace, Inc., a US-based clinical research services company with expertise of provid...

2019-05-06 07:50 1011

WuXi AppTec Reports Strong 2018 Annual Results

SHANGHAI, March 22, 2019 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 02359.HK), a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces its audited annual results for the year endedDecember 31, ...

2019-03-22 20:47 1016

WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange

HONG KONG and SHANGHAI, Dec. 13, 2018 /PRNewswire/ -- WuXi AppTec Co., Ltd. ("WuXi AppTec" or "the Company"; Stock code: 603259.SH/2359.HK) today announced the listing of approximately 116 million H-shares on the Main Board of the Hong Kong Stock Exchange. Based on the offer price ofHK$68 per sha...

2018-12-13 10:23 1126

WuXi AppTec Opens Its New Medical Device Testing Center in Suzhou

SUZHOU, China, Nov. 16, 2018 /PRNewswire/ -- WuXi AppTec announces today that its Laboratory Testing Division's new Medical Device Testing Center opens today in Suzhou,China. This marks the full implementation of WuXi AppTec's medical device testing capabilities in the Chinese market, which works...

2018-11-16 18:00 573

WuXi AppTec and Insilico Medicine Link Next-Generation Artificial Intelligence and Drug Discovery

WuXi AppTec and Insilico Medicine establish a close strategic collaboration to integrate next-generation artificial intelligence with drug discovery BALTIMORE, Maryland and SHANGHAI, June 12, 2018 /PRNewswire/ -- Insilico Medicine, aBaltimore-based next-generation artificial intelligence company ...

2018-06-12 10:40 1101

WuXi AppTec Announces Listing of Initial Public Offering of Common Stock on Shanghai Stock Exchange

SHANGHAI, May 7, 2018 /PRNewswire/ -- WuXi AppTec Co., Ltd. ("WuXi AppTec" or "the Company"; Stock Code: 603259), a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced listing of its initial public offering of 104,198,600 shar...

2018-05-08 11:44 899